Development of ceftazidime resistance in an acute burkholderia pseudomallei infection

Infection and Drug Resistance

Volumn 5, Issue 1, 2012, Pages 129-132

  Sarovich, Derek S ^a,b   Price, Erin P ^a,b   Limmathurotsakul, Direk ^c   Cook, James M ^a   von Schulze, Alex T ^a   Wolken, Spenser R ^a   Keim, Paul ^a   Refidaff, Cref ^c,d   Pearson, Talima ^a  

^a NORTHERN ARIZONA UNIVERSITY   (United States)

^b MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^c MAHIDOL UNIVERSITY   (Thailand)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Antibiotic resistance; Burkholderia pseudomallei; Ceftazidime; Melioidosis; Pena; lactamase

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAMASE; CEFTAZIDIME; CEFTRIAXONE; CLINDAMYCIN; IMIPENEM; MEROPENEM; PENA PROTEIN; PROLINE; SERINE; UNCLASSIFIED DRUG;

ABSCESS; ADULT; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; BIOASSAY; BURKHOLDERIA PSEUDOMALLEI; CASE REPORT; CLONAL SPECIES; DRUG RESPONSE; DRUG TREATMENT FAILURE; DYSPNEA; FEVER; HUMAN; HYPOTENSION; IMMUNOFLUORESCENCE TEST; LEG DISEASE; MALE; MELIOIDOSIS; MIXED INFECTION; NONHUMAN; PLEURA EFFUSION; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT DISEASE; REINFECTION; SENSITIVITY ANALYSIS; THORAX RADIOGRAPHY; TREATMENT DURATION;

EID: 84871023451     PISSN: 11786973     EISSN: None     Source Type: Journal    
DOI: 10.2147/idr.s35529     Document Type: Article

References (22)

1. Currie BJ, Dance DA, Cheng AC. The global distribution of Burkholderia pseudomallei and melioidosis: an update. Trans R Soc Trop Med Hyg. 2008;102(Suppl 1):S1-S4.
2. Wuthiekanun V, Amornchai P, Saiprom N, et al. Survey of antimicro- bial resistance in clinical Burkholderia pseudomallei isolates over two decades in Northeast Thailand. Antimicrob Agents Chemother. 2011; 55(11):5388-5391.
3. Jenney AW, Lum G, Fisher DA, Currie BJ. Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis. Int J Antimicrob Agents. 2001; 17(2):109-113.
4. Cheng AC, Currie BJ. Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev. 2005;18(2):383-416.
5. Sarovich DS, Price E P, Von Schulze AT, et al. Characterization of ceftazidime resistance mechanisms in clinical isolates of Burkholderia pseudomallei from Australia. PLoS One. 2012;7(2):e30789.
6. Chantratita N, Rholl DA, Sim B, et al. Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in Burkholderia pseudomallei. Proc Natl Acad Sci U S A. 2011;108(41):17165-17170.
7. Sam IC, See KH, Puthucheary SD. Variations in ceftazidime and amoxicillin-clavulanate susceptibilities within a clonal infec- tion of Burkholderia pseudomallei. J Clin Microbiol. 2009;47(5): 1556-1558.
8. Kung CT, Lee CH, Li CJ, Lu HI, Ko SF, Liu J W. Development of ceftazi- dime resistance in Burkholderia pseudomallei in a patient experiencing melioidosis with mediastinal lymphadenitis. Ann Acad Med Singapore. 2010;39(12):945-947.
9. Behera B, Prasad Babu T, Kamalesh A, Reddy G. Ceftazidime resistance in Burkholderia pseudomallei: frst report from India. Asian Pac J Trop Med. 2012;5(4):329-330.
10. Hayden HS, Lim R, Brittnacher MJ, et al. Evolution of Burkholderia pseudomallei in recurrent melioidosis. PLoS One. 2012;7(5):e36507.
11. Tribuddharat C, Moore RA, Baker P, Woods DE. Burkholderia pseudo- mallei class A β-lactamase mutations that confer selective resistance against ceftazidime or clavulanic acid inhibition. Antimicrob Agents Chemother. 2003;47(7):2082-2087.
12. Walsh AL, Smith MD, Wuthiekanun V, et al. Immunofuorescence microscopy for the rapid diagnosis of melioidosis. J Clin Pathol. 1994; 47(4):377-379.
13. Price E P, Hornstra HM, Limmathurotsakul D, et al. Within-host evolu- tion of Burkholderia pseudomallei in four cases of acute melioidosis. PLoS Pathog. 2010;6(1):e1000725.
14. Limmathurotsakul D, Wuthiekanun V, Chantratita N, et al. Simultaneous infection with more than one strain of Burkholderia pseudomallei is uncom- mon in human melioidosis. J Clin Microbiol. 2007;45(11): 3830-3832.
15. Hezard N, Cornillet P, Droulle C, Gillot L, Potron G, Nguyen P. Factor V Leiden: detection in whole blood by ASA PCR using an additional mis- match in antepenultimate position. Thromb Res. 1997;88(1):59-66.
16. Ambler R P, Coulson AF, Frere JM, et al. A standard numbering scheme for the class A β-lactamases. Biochem J. 1991;276(Pt 1):269-270.
17. Germer S, Higuchi R. Single-tube genotyping without oligonucleotide probes. Genome Res. 1999;9(1):72-78.
18. Rholl DA, Papp-Wallace KM, Tomaras AP, Vasil ML, Bonomo RA, Schweizer H P. Molecular investigations of PenA-mediated β-lactam resistance in Burkholderia pseudomallei. Front Microbiol. 2011; 2:139.
19. Currie BJ, Ward L, Cheng AC. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study. PLoS Negl Trop Dis. 2010;4(11):e900.
20. Limmathurotsakul D, Chaowagul W, Chantratita N, et al. A simple scor- ing system to differentiate between relapse and re-infection in patients with recurrent melioidosis. PLoS Negl Trop Dis. 2008;2(10):e327.
21. Pearson T, U'Ren JM, Schupp JM, et al. VNTR analysis of selected outbreaks of Burkholderia pseudomallei in Australia. Infect Genet Evol. 2007;7(4):416-423.
22. Holden MT, Titball RW, Peacock SJ, et al. Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. Proc Natl Acad Sci U S A. 2004;101(39):14240-14245.